IGF2BP3 and small cell lung carcinoma: Consistent with the microarray data, hsa-miR-183 and hsa-miR-182 were significantly upregulated (Figures 7(a) and 7(b)) and IGF2BP3 was downregulated (Figure 7(c)) between 20 pairs of NLTs and SCLCTs which indicated that hsa-miR-183, hsa-miR-182, and IGF2BP3 could be the candidate biomarkers for SCLC.